GU CONNECT expert, Assoc. Prof. Martin Pichler provides a kidney cancer update from ASCO GU 2020 for you.


Kidney cancer update by Assoc. Prof. Martin Pichler, Medical University of Graz, Austria

 

Martin Pichler obtained his MD at the Medical University of Graz in 2006, and his Master of Science in Molecular Biology at the Karl-Franzens University of Graz, Austria. Martin continued his cancer research training in different places, including The UT MD Anderson Cancer Center, Houston, USA (where he is Adjunct Faculty member at the Department of Experimental Therapeutics). He currently works as a medical oncologist with special focus on Urogential- and Gastrointestinal cancer, at the Division of Oncology, Medical University of Graz, Austria. He currently holds the research managing director position of this division and is the Head of the Research Unit for Non-Coding RNAs and Genome Editing in Cancer. His main research focus is to study molecular mechanisms of cancer biology, prognostic biomarker studies and clinical trials. He received several awards, grants and published about 170 peer-reviewed papers so far (forschung.medunigraz.at).
Programme summary
Watch the video now
Other episodes of this series
GU CONNECT: Update from ASCO GU 2020

GU CONNECT: Update from ASCO GU 2020

Episode 1: Prostate Cancer
GU CONNECT Update from ASCO GU 2020

GU CONNECT Update from ASCO GU 2020

Episode 2: Urothelial Cancer
GU CONNECT Update from ASCO GU 2020

GU CONNECT Update from ASCO GU 2020

Episode 3: Kidney Cancer Current Episode
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
Supporter Acknowledgement
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU CONNECT

GU CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

conference-update Conference update

Episode

3

of 3

episode
Oncology 
How are new data shaping the landscape in HER2-mutant NSCLC?

Insights from WCLC 2026

Experts
Dr Joshua Sabari
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • clock 5 MIN
  • calendar Sep 2026

Educational programme supported by an Independent Educational Grant from Bayer.
blueprint BluePrintInfographic / Flashcard
Oncology 
Biomarker testing in non-small cell lung cancer (NSCLC)

Insights from patients and caregivers

Experts
Prof. Christian Rolfo, Prof. Fernando López-Ríos, Dr Rodrigo Paredes de la Fuente, Anne-Marie Baird, Amy C. Moore, Shani Shilo
Endorsed by
LUNGevity The Israeli Lung Cancer Foundation
Biomarker Collaborative NTRKers Lung Cancer Europe
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer.
conference-update Conference update
Oncology Hemato-oncology 
Myelofibrosis: Navigating unmet needs and overcoming clinical challenges

Expert perspectives on clinical trial highlights from EHA 2026

Experts
Prof. Francesco Passamonti, Prof. Claire Harrison
  • download Downloadable
    Resources
  • clock 6 MIN
  • calendar Jul 2026

Brought to you by COR2ED Medical Affairs in collaboration with Menarini Stemline. This programme is intended for HCPS outside the UK. MED---2600258
micro-learning Micro learning - Video, slides and more
Oncology 
The evolving treatment landscape in HER2-mutant NSCLC

Expert insights on how the latest evidence is shaping clinical practice

Experts
Dr Devika Das, Dr Tom Newsom-Davis
Endorsed by
ICAN international cancer advocacy network Biomarker Collaborative Exon20group
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Jul 2026
  • Non-accredited Independent Medical Education

Educational programme supported by an Independent Educational Grant from Bayer